A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

NCT02525536 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Advanced Solid

Interventions

DRUG: Trebananib 3 mg/kg
DRUG: Trebananib 10 mg/kg
DRUG: Trebananib 30 mg/kg

Sponsor

Takeda